HCC CONNECT has summarised the highlights of the recent congress of the American Association for the Study of Liver Diseases (AASLD) 2016 in Boston for you.

Dr Sadahisa Ogasawara obtained his medical degree in 2004 and his PhD in 2012 from Chiba University (Japan). He is a hepatologist and works at Chiba University Hospital. He is currently an Assistant Professor of the cranial research center at Chiba University Hospital as well as on the staff of the Department of Gastroenterology, Chiba University, Graduate School of Medicine, where his research is focused on loco-regional treatments and systemic therapies of hepatocellular carcinoma. Relevant Publications Ogasawara S, Chiba T, Motoyama T, Kanogawa N, Saito T, Shinozaki Y, Suzuki E, Ooka Y, Tawada A, Kato H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Prognostic significance of concurrent hypovascular and hypervascular nodules in patients with hepatocellular carcinoma. PLoS One 2016 Sep 20; 11(9): e0163119. Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of sorafenib outcome: focusing on the clinical course in patients with hepatocellular carcinoma. PLoS One 2016 Aug 18; 11(8): e0161303. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Azemoto R, Shinozaki M, Yoshikawa M, Yokosuka O. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One 2015 Apr 28; 10(4): e0125244. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015 Jun; 33(3): 729-39. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014; 87(6): 330-41.

Programme summary
Watch the video now
Other episodes of this series
HCC CONNECT update from AASLD 2016

HCC CONNECT update from AASLD 2016

Episode 3 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim
animated-video Animated Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.